focus -WSS

focus

author：entertainment 2025-08-23 05:22:57 - browse：837

The back of three medicine containers, a bottle in between two boxes, all showing labels — coverage from STAT — Adobe

After a drug enters the market, it’s up to Food and Drug Administration regulators to ensure its continued safety and efficacy. A recent New York Times story suggests that, in the case of the popular asthma drug Singulair, the FDA fell short — both because the agency delayed action for years on reports from patient advocates and independent groups that the drug could cause suicidal thoughts, and because when it did add a warning label about its potential side effects in 2020, clinicians and patients still weren’t always aware of the risks.

Experts say that the Singulair incident highlights a flawed system, both in the U.S. and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address.

“The question is, how safe do you want to be?” said Ameet Sarpatwari, the assistant director of the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital. Ideally, he said, the FDA should be able to both stay on top of safety concerns and avoid unnecessarily restricting access to drugs. “Are we at the right balance? I think there are definitely situations for many drugs where you can say, no, we’re not really at the right balance, and the FDA should be taking a more aggressive stance in promoting patient safety.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： RSV shot was 90% effective at preventing hospitalizations in kids

focus

hotspot

WSS

What it’s like to watch children die of measles

How to keep neuroscience’s past racism from being its future

Violet CEO on training clinicians to promote more inclusive care

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

CDC marks new Covid

hotspot

focus

knowledge

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Christmas in the PICU brings some surprising joy

Medical leaders decry Supreme Court decision on affirmative action

Amylyx ALS drug fails large clinical trial

Hepatitis C has a cure — but many Americans still lack access to it

Grail spinoff by Illumina should end disastrous merger attempt

After affirmative action ruling, medical educators look to 'holistic review'

Medicare Advantage beneficiaries sue Humana over algorithm use

Wikipedia

In Spain, a hospital brews its own CAR

In his State of the Union, Biden takes clear aim at 'Big Pharma'

How to keep neuroscience’s past racism from being its future

Violet CEO on training clinicians to promote more inclusive care

Keeping primary care docs in field isn't impossible, says AAFP CEO

Keeping primary care docs in field isn't impossible, says AAFP CEO

explore

focus

hotspot

explore